![]() | ![]() |
Formats:
|
||||||||||||
Copyright © 2007, American Society for Microbiology Humanized NOD/SCID/IL2Rγnull Mice Transplanted with Hematopoietic Stem Cells under Nonmyeloablative Conditions Show Prolonged Life Spans and Allow Detailed Analysis of Human Immunodeficiency Virus Type 1 Pathogenesis Department of Virology, Division of Medical Science, Medical Research Institute, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan,1 Open Research Center for Genome and Infectious Disease Control, Nihon University School of Medicine, 30-1 Oyaguchikami-chou, Itabashi-ku, Tokyo 173-8610, Japan,2 AIDS Research Center, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan,3 Department of Infectious Diseases, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 154-8567, Japan,4 Department of Molecular Virology, Graduate School of Medicine, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan,5 Central Institute for Experimental Animals, 1430 Nogawa, Miyamae-ku, Kawasaki, Kanagawa 216-0001, Japan,6 Department of Pediatrics and Child Health, Nihon University School of Medicine, 30-1 Oyaguchikami-chou, Itabashi-ku, Tokyo 173-8610, Japan7 *Corresponding author. Mailing address for Naoki Yamamoto: AIDS Research Center, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan. Phone: 81-3-5285-1111. Fax: 81-3-5285-1165. E-mail: nyama/at/nih.go.jp. Mailing address for Norio Shimizu: Department of Virology, Division of Medical Science, Medical Research Institute, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan. Phone and fax: 81-3- 5803-5811. E-mail: nshivir/at/tmd.ac.jp Received June 21, 2007; Accepted September 3, 2007. This article has been cited by other articles in PMC.Abstract In a previous study, we demonstrated that humanized NOD/SCID/IL2Rγnull (hNOG) mice constructed with human hematopoietic stem cells (HSCs) allow efficient human immunodeficiency virus type 1 (HIV-1) infection. However, HIV-1 infection could be monitored for only 43 days in the animals due to their short life spans. By transplanting HSCs without any myeloablation methods, the mice successfully survived longer than 300 days with stable engraftment of human cells. The mice showed high viremia state for more than the 3 months examined, with systemic HIV-1 infection and gradual decrease of CD4+ T cells analogous to that in humans. These capacities of the hNOG mice are very attractive for modeling mechanisms of AIDS progression and therapeutic strategy. One of the main problems in the field of human immunodeficiency virus type 1 (HIV-1) research is the lack of suitable small animal models for studying the virological and pathogenic aspects of human HIV-1 infection. To overcome the drawback that HIV-1 does not replicate in rodent cells, severe combined immunodeficiency (SCID) mice, engrafted with human peripheral blood mononuclear cells (hu-PBL-SCID) (16) or human fetal thymus and liver tissue [SCID-hu (Thy/Liv)] (18), have been used for the small animal models of HIV-1 infection. However, these mouse models fall short of accurately mirroring human HIV infection because of their short infection spans (17), limited infection of lymphoid tissues (15), and partial infection to coreceptor tropic HIVs (4, 10, 13). Considering the significant advantages of developing a mouse model for HIV-1 infection, we previously introduced a novel HIV-1 mouse model using nonobese diabetic (NOD)/SCID/interleukin-2 receptor (IL-2R) gamma chain-knocked-out (NOG) mice (22). Multilineage human cells, including T, B, NK cells, monocytes/macrophages, and dendritic cells (DCs) differentiate in the mice when transplanted with human CD34+ hematopoietic stem cells (HSCs) (6, 9, 22). These mice show high levels of susceptibility to both CCR5 (R5)- and CXCR4 (X4)-tropic HIVs with intense plasma viral loads lasting for over 40 days (22). Thus, this mouse model may be valuable for the study of HIV-1 infection. However, a serious problem remains. The mice showed symptoms of a wasting condition and a hunched back 5 to 7 months after HSC transplantation, following which most of them died. This life span is not sufficient if we are to better understand HIV pathogenesis and to develop novel anti-HIV countermeasures, because more than 4 months posttransplantation is required for the development of human T cells before HIV-1 can be studied in mice. In past studies for the construction of humanized mouse models using NOD/SCID, β2 microglobulin-deficient NOD/SCID (NOD/SCID/B2mnull) or NOG mice, the mice were subjected to total body irradiation or given drugs for HSC transplantation (6, 9, 11, 14, 21, 23). Since NOG mice do not develop any thymic lymphomas in contrast to NOD/SCID or NOD/SCID/B2mnull mice (3, 19), the irradiation might influence the reduction of their life spans. In this study, we therefore searched for optimal conditions for HSC transplantation and consequently found that in NOG mice, myeloablation procedures were not required for human cell generation. Importantly, these mice stably survived longer than 300 days after the HSC transplantation, which allowed further investigation of HIV-1 pathogenesis and progression to disease state in the animals. NOG mice constructed with HSCs without myeloablation showed prolonged survival time and stable human cell generation. Six- to eight-week-old female NOG mice were obtained from the Central Institute for Experimental Animals (Kawasaki, Japan), and human cord blood-derived CD34+ HSCs (2 × 104 to 12 × 104 cells) were injected intravenously with or without irradiation. As shown in Fig. Fig.1A,1A
We further analyzed the development of human monocytes, macrophages, and DCs in the mice with transplanted HSCs without irradiation. Human CD14+ monocytes were detected in peripheral blood and BM using flow cytometry (Fig. (Fig.1F),1F hNOG mice induced systemic and long-lasting HIV-1 infection with CD4+ T-cell depletion. We prepared 29 stem cell-transplanted hNOG mice and inoculated them intravenously with a high dose of R5-tropic HIV-1JRCSF (65,000 50% tissue culture infective doses [TCID50]), X4-tropic HIV-1MNp (20,000 TCID50), or X4-tropic HIV-1NL4-3 (60,000 TCID50) at 122 to 150 days posttransplantation. Then, plasma viral RNA copy numbers were measured at successive time points. The mice showed marked, long-lasting viremia state for more than 3 months, reaching the highest levels of 3.0 × 105 copies/ml from HIV-1JRCSF-infected mice, 3.7 × 106 copies/ml from HIV-1MNp-infected mice, and 7.8 × 106 copies/ml from HIV-1NL4-3-infected mice (Fig. (Fig.2A).2A
All the mice were sacrificed within 4 months postinfection, and the percentages of CD4+ and CD8+ cells in lymphoid tissues were analyzed by flow cytometry. In a representative HIV-1-infected mouse, as shown in Fig. Fig.2B,2B
In one mouse from each R5- and X4-tropic HIV-infected group, HIV-1 proviral DNA copy numbers in various organs were measured by real-time PCR assay (Table 2). High HIV DNA copy numbers were detected in the spleen, BM, and LN of the R5-tropic HIV-1-infected mouse and in the thymus, spleen, and LN of the X4-tropic HIV-1-infected mice. In addition, HIV DNA copies were detectable in various other organs, including the lung, liver, ovary, and uterus. The fact that many human CD68+ macrophages, the source of HIV-1 throughout the body (7, 8), were recognized in these organs (22) (Fig. (Fig.1H)1H
To further investigate the progression of CD4+ T-cell depletion by HIV-1 infection, 25 mice 120 to 151 days after HSC transplantation were randomly separated into groups of uninfected control mice (n = 7), HIV-1JRCSF-inoculated mice (n = 7), HIV-1MNp-inoculated mice (n = 5), and HIV-1NL4-3-inoculated mice (n = 6), and then CD4/CD8 ratios and absolute CD4+ T-cell numbers in peripheral blood were monitored at regular intervals. X4-tropic HIV-infected mice showed gradual decreases of their CD4/CD8 ratios and CD4+ T-cell numbers, which eventually resulted in an almost complete depletion from peripheral blood (Fig. (Fig.2D).2D In this study, we successfully prolonged the life span of hNOG mice by improving the HSC transplantation method and further clarified characteristics of HIV-1 infection in the mice including the following: (i) high levels of viremia lasting over 3 months, (ii) CD4+ T-cell depletion in peripheral blood and spleen regardless of thymic T-cell loss, (iii) systemic HIV-1 infection not only in lymphoid tissues but also in various other organs, and (iv) a different rate of CD4+ T-cell depletion for R5- versus X4-tropic HIV-1 strains. Recently, several studies on HIV-1 infection in Rag2−/− γc−/− mice, transplanted with HSCs at birth, have also been reported (1, 2, 5, 24). The mice showed high susceptibility to both R5- and X4-tropic HIVs and long-term viremia with CD4+ T-cell depletion, which is partly similar to our present results. However, the efficiency of human cell generation in Rag2−/− γc−/− mice strongly depends on the dose of irradiation, and levels of chimerism in mice are not stable even receiving 550 to 750 cGy irradiation, which does eventually induces reduction of their life spans (5). In contrast, very stable engraftment of HSCs and subsequent human cell generation were noted in our hNOG mice even without any myeloablation procedures. Their long life spans and long-term human cell reconstitution allowed persistent HIV-1 infections mirroring HIV-1 infections in humans. Thus, this hNOG mouse system is a very useful tool as an advanced mouse model for the study of AIDS progression and long-term evaluation of new anti-HIV-1 drugs. Acknowledgments We thank Tomohiro Morio, Ken Watanabe, and Eiko Ogata of Tokyo Medical and Dental University for their helpful comments and skillful technical support. We are also grateful to Yukari Sasaki and Kazuhiro Takimoto of the National Institute of Infectious Diseases and Teruaki Tanaka and Junichi Fujita of the Nihon University School of Medicine for their management of animals. Human umbilical cord blood samples were obtained from the Tokyo Cord Blood Bank of the Nihon University School of Medicine. This work was supported by a grant from the Ministry of Education, Culture, Sports, Science, and Technology to promote open research for young academics and specialists. Footnotes Published ahead of print on 19 September 2007.REFERENCES 1. Baenziger, S., R. Tussiwand, E. Schlaepfer, L. Mazzucchelli, M. Heikenwalder, M. O. Kurrer, S. Behnke, J. Frey, A. Oxenius, H. Joller, A. Aguzzi, M. G. Manz, and R. F. Speck. 2006. Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2−/− γc−/− mice. Proc. Natl. Acad. Sci. USA 103:15951-15956. [PubMed] 2. Berges, B. K., W. H. Wheat, B. E. Palmer, E. Connick, and R. Akkina. 2006. HIV-1 infection and CD4 T cell depletion in the humanized Rag2−/− γc−/− (RAG-hu) mouse model. Retrovirology 3:76. [PubMed] 3. Christianson, S. W., D. L. Greiner, R. A. Hesselton, J. H. Leif, E. J. Wagar, I. B. Schweitzer, T. V. Rajan, B. Gott, D. C. Roopenian, and L. D. Shultz. 1997. Enhanced human CD4+ T cell engraftment in beta2-microglobulin-deficient NOD-scid mice. J. Immunol. 158:3578-3586. [PubMed] 4. Fais, S., C. Lapenta, S. M. Santini, M. Spada, S. Parlato, M. Logozzi, P. Rizza, and F. Belardelli. 1999. Human immunodeficiency virus type 1 strains R5 and X4 induce different pathogenic effects in hu-PBL-SCID mice, depending on the state of activation/differentiation of human target cells at the time of primary infection. J. Virol. 73:6453-6459. [PubMed] 5. Gorantla, S., H. Sneller, L. Walters, J. G. Sharp, S. J. Pirruccello, J. T. West, C. Wood, S. Dewhurst, H. E. Gendelman, and L. Poluektova. 2007. Human immunodeficiency virus type 1 pathobiology studied in humanized BALB/c-Rag2−/−γc−/− mice. J. Virol. 81:2700-2712. [PubMed] 6. Hiramatsu, H., R. Nishikomori, T. Heike, M. Ito, K. Kobayashi, K. Katamura, and T. Nakahata. 2003. Complete reconstitution of human lymphocytes from cord blood CD34+ cells using the NOD/SCID/γcnull mice model. Blood 102:873-880. [PubMed] 7. Igarashi, T., C. R. Brown, Y. Endo, A. Buckler-White, R. Plishka, N. Bischofberger, V. Hirsch, and M. A. Martin. 2001. Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): implications for HIV-1 infections of humans. Proc. Natl. Acad. Sci. USA 98:658-663. [PubMed] 8. Igarashi, T., O. K. Donau, H. Imamichi, M. J. Dumaurier, R. Sadjadpour, R. J. Plishka, A. Buckler-White, C. Buckler, A. F. Suffredini, H. C. Lane, J. P. Moore, and M. A. Martin. 2003. Macrophage-tropic simian/human immunodeficiency virus chimeras use CXCR4, not CCR5, for infections of rhesus macaque peripheral blood mononuclear cells and alveolar macrophages. J. Virol. 77:13042-13052. [PubMed] 9. Ito, M., H. Hiramatsu, K. Kobayashi, K. Suzue, M. Kawahata, K. Hioki, Y. Ueyama, Y. Koyanagi, K. Sugamura, K. Tsuji, T. Heike, and T. Nakahata. 2002. NOD/SCIDγcnull mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100:3175-3182. [PubMed] 10. Kaneshima, H., L. Su, M. L. Bonyhadi, R. I. Connor, D. D. Ho, and J. M. McCune. 1994. Rapid-high, syncytium-inducing isolates of human immunodeficiency virus type 1 induce cytopathicity in the human thymus of the SCID-hu mouse. J. Virol. 68:8188-8192. [PubMed] 11. Kollet, O., A. Peled, T. Byk, H. Ben-Hur, D. Greiner, L. Shultz, and T. Lapidot. 2000. β2 Microglobulin-deficient (B2mnull) NOD/SCID mice are excellent recipients for studying human stem cell function. Blood 95:3102-3105. [PubMed] 12. Koot, M., I. P. Keet, A. H. Vos, R. E. de Goede, M. T. Roos, R. A. Coutinho, F. Miedema, P. T. Schellekens, and M. Tersmette. 1993. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann. Intern. Med. 118:681-688. [PubMed] 13. Koyanagi, Y., Y. Tanaka, J. Kira, M. Ito, K. Hioki, N. Misawa, Y. Kawano, K. Yamasaki, R. Tanaka, Y. Suzuki, Y. Ueyama, E. Terada, T. Tanaka, M. Miyasaka, T. Kobayashi, Y. Kumazawa, and N. Yamamoto. 1997. Primary human immunodeficiency virus type 1 viremia and central nervous system invasion in a novel hu-PBL-immunodeficient mouse strain. J. Virol. 71:2417-2424. [PubMed] 14. Matsumura, T., Y. Kametani, K. Ando, Y. Hirano, I. Katano, R. Ito, M. Shiina, H. Tsukamoto, Y. Saito, Y. Tokuda, S. Kato, M. Ito, K. Motoyoshi, and S. Habu. 2003. Functional CD5+ B cells develop predominantly in the spleen of NOD/SCID/γcnull (NOG) mice transplanted either with human umbilical cord blood, bone marrow, or mobilized peripheral blood CD34+ cells. Exp. Hematol. 31:789-797. [PubMed] 15. McCune, J., H. Kaneshima, J. Krowka, R. Namikawa, H. Outzen, B. Peault, L. Rabin, C. C. Shih, E. Yee, M. Lieberman, I. Weissman, and L. Shultz. 1991. The SCID-hu mouse: a small animal model for HIV infection and pathogenesis. Annu. Rev. Immunol. 9:399-429. [PubMed] 16. Mosier, D. E., R. J. Gulizia, S. M. Baird, D. B. Wilson, D. H. Spector, and S. A. Spector. 1991. Human immunodeficiency virus infection of human-PBL-SCID mice. Science 251:791-794. [PubMed] 17. Mosier, D. E., R. J. Gulizia, P. D. MacIsaac, B. E. Torbett, and J. A. Levy. 1993. Rapid loss of CD4+ T cells in human-PBL-SCID mice by noncytopathic HIV isolates. Science 260:689-692. [PubMed] 18. Namikawa, R., H. Kaneshima, M. Lieberman, I. L. Weissman, and J. M. McCune. 1988. Infection of the SCID-hu mouse by HIV-1. Science 242:1684-1686. [PubMed] 19. Shultz, L. D., P. A. Schweitzer, S. W. Christianson, B. Gott, I. B. Schweitzer, B. Tennent, S. McKenna, L. Mobraaten, T. V. Rajan, D. L. Greiner, et al. 1995. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J. Immunol. 154:180-191. [PubMed] 20. Tersmette, M., R. A. Gruters, F. de Wolf, R. E. de Goede, J. M. Lange, P. T. Schellekens, J. Goudsmit, H. G. Huisman, and F. Miedema. 1989. Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J. Virol. 63:2118-2125. [PubMed] 21. Ueda, T., H. Yoshino, K. Kobayashi, M. Kawahata, Y. Ebihara, M. Ito, S. Asano, T. Nakahata, and K. Tsuji. 2000. Hematopoietic repopulating ability of cord blood CD34+ cells in NOD/Shi-scid mice. Stem Cells 18:204-213. [PubMed] 22. Watanabe, S., K. Terashima, S. Ohta, S. Horibata, M. Yajima, Y. Shiozawa, M. Z. Dewan, Z. Yu, M. Ito, T. Morio, N. Shimizu, M. Honda, and N. Yamamoto. 2007. Hematopoietic stem cell-engrafted NOD/SCID/IL2Rγnull mice develop human lymphoid systems and induce long-lasting HIV-1 infection with specific humoral immune responses. Blood 109:212-218. [PubMed] 23. Yahata, T., K. Ando, Y. Nakamura, Y. Ueyama, K. Shimamura, N. Tamaoki, S. Kato, and T. Hotta. 2002. Functional human T lymphocyte development from cord blood CD34+ cells in nonobese diabetic/Shi-scid, IL-2 receptor γ null mice. J. Immunol. 169:204-209. [PubMed] 24. Zhang, L., G. I. Kovalev, and L. Su. 2007. HIV-1 infection and pathogenesis in a novel humanized mouse model. Blood 109:2978-2981. [PubMed] |
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||
Science. 1991 Feb 15; 251(4995):791-4.
[Science. 1991]Science. 1988 Dec 23; 242(4886):1684-6.
[Science. 1988]Science. 1993 Apr 30; 260(5108):689-92.
[Science. 1993]Annu Rev Immunol. 1991; 9():399-429.
[Annu Rev Immunol. 1991]J Virol. 1999 Aug; 73(8):6453-9.
[J Virol. 1999]Blood. 2007 Jan 1; 109(1):212-8.
[Blood. 2007]Blood. 2003 Aug 1; 102(3):873-80.
[Blood. 2003]Blood. 2002 Nov 1; 100(9):3175-82.
[Blood. 2002]Blood. 2003 Aug 1; 102(3):873-80.
[Blood. 2003]Blood. 2002 Nov 1; 100(9):3175-82.
[Blood. 2002]Blood. 2000 May 15; 95(10):3102-5.
[Blood. 2000]Exp Hematol. 2003 Sep; 31(9):789-97.
[Exp Hematol. 2003]Stem Cells. 2000; 18(3):204-13.
[Stem Cells. 2000]Blood. 2007 Jan 1; 109(1):212-8.
[Blood. 2007]Blood. 2007 Jan 1; 109(1):212-8.
[Blood. 2007]Proc Natl Acad Sci U S A. 2001 Jan 16; 98(2):658-63.
[Proc Natl Acad Sci U S A. 2001]J Virol. 2003 Dec; 77(24):13042-52.
[J Virol. 2003]Blood. 2007 Jan 1; 109(1):212-8.
[Blood. 2007]Ann Intern Med. 1993 May 1; 118(9):681-8.
[Ann Intern Med. 1993]J Virol. 1989 May; 63(5):2118-25.
[J Virol. 1989]Proc Natl Acad Sci U S A. 2006 Oct 24; 103(43):15951-6.
[Proc Natl Acad Sci U S A. 2006]Retrovirology. 2006 Nov 1; 3():76.
[Retrovirology. 2006]J Virol. 2007 Mar; 81(6):2700-12.
[J Virol. 2007]Blood. 2007 Apr 1; 109(7):2978-81.
[Blood. 2007]